L
Lihua Hou
Researcher at Academy of Military Medical Sciences
Publications - 37
Citations - 1875
Lihua Hou is an academic researcher from Academy of Military Medical Sciences. The author has contributed to research in topics: Medicine & Biology. The author has an hindex of 9, co-authored 19 publications receiving 1017 citations.
Papers
More filters
Journal ArticleDOI
A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2.
Chi Xiangyang,Renhong Yan,Jun Zhang,Zhang Guanying,Yuanyuan Zhang,Hao Meng,Zhe Zhang,Pengfei Fan,Dong Yunzhu,Yilong Yang,Chen Zhengshan,Yingying Guo,Jinlong Zhang,Yaning Li,Xiaohong Song,Chen Yi,Lu Xia,Ling Fu,Lihua Hou,Junjie Xu,Changming Yu,Jianmin Li,Qiang Zhou,Wei Chen +23 more
TL;DR: The epitope of 4A8 is defined as the N-terminal domain (NTD) of the S protein by determining with cryo–eletron microscopy its structure in complex with the Sprotein, which points to the NTD as a promising target for therapeutic mAbs against COVID-19.
Journal ArticleDOI
A single dose of an adenovirus-vectored vaccine provides protection against SARS-CoV-2 challenge.
Shipo Wu,Gongxun Zhong,Jun Zhang,Lei Shuai,Zhe Zhang,Zhiyuan Wen,Busen Wang,Zhao Zhenghao,Xiaohong Song,Chen Yi,Renqiang Liu,Ling Fu,Jie Zhang,Qiang Guo,Chong Wang,Yilong Yang,Fang Ting,Peng Lv,Jinliang Wang,Junjie Xu,Jianmin Li,Changming Yu,Lihua Hou,Zhigao Bu,Wei Chen +24 more
TL;DR: It is found that a single vaccination with a replication-defective human type 5 adenovirus encoding the SARS-CoV-2 spike protein (Ad5-nCoV) protect mice completely against mouse-adapted Sars-Co V-2 infection in the upper and lower respiratory tracts.
Journal ArticleDOI
Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial.
Shipo Wu,Jianying Huang,Zhe Zhang,Jianyuan Wu,Jinlong Zhang,Hanning Hu,Tao Zhu,Jun Zhang,Lin Luo,Pengfei Fan,Busen Wang,Chang Chen,Chen Yi,Xiaohong Song,Yudong Wang,Weixue Si,Tianjian Sun,Xinghuan Wang,Lihua Hou,Wei Chen +19 more
TL;DR: In this article, the safety and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults without COVID19 from China was evaluated.
Journal ArticleDOI
Heterologous AD5-nCOV plus CoronaVac versus homologous CoronaVac vaccination: a randomized phase 4 trial
Jingxin Li,Lihua Hou,Xiling Guo,Pengfei Jin,Shipo Wu,Jiahong Zhu,Hongxing Pan,Xue Wang,Zexing Song,Jingxuan Wan,Lunbiao Cui,Junqiang Li,Yin Chen,Xue-Wen Wang,L. Jin,Jingxian Liu,Fengjuan Shi,Xiaoyu Xu,Tao Zhu,Wei Chen,Fengcai Zhu +20 more
TL;DR: In this paper , the authors evaluated the safety and immunogenicity of the recombinant adenovirus type 5 (AD5)-vectored COVID-19 vaccine Convidecia as a heterologous booster versus those of CoronaVac as homologous boost in adults previously vaccinated with CoronaVAC in an ongoing, randomized, observer-blinded, parallel-controlled phase 4 trial.
Posted ContentDOI
A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability
Chi Xiangyang,Renhong Yan,Jun Zhang,Zhang Guanying,Yuanyuan Zhang,Hao Meng,Zhe Zhang,Pengfei Fan,Dong Yunzhu,Yilong Yang,Chen Zhengshan,Yingying Guo,Jinlong Zhang,Yaning Li,Xiaohong Song,Chen Yi,Lu Xia,Ling Fu,Lihua Hou,Junjie Xu,Changming Yu,Jianmin Li,Qiang Zhou,Wei Chen +23 more
TL;DR: A new vulnerable epitope of the S protein is discovered and promising neutralizing mAbs are identified as potential clinical therapy for COVID-19, the pandemic of coronavirus disease 2019.